Silence Therapeutics, a leading RNA interference therapeutics company, announces that it has entered into an agreement with one of the world's leading global pharmaceutical companies to investigate the application of Silence's proprietary DACC delivery technology for intravenous delivery of short interfering RNA sequences to the pulmonary vascular endothelium.
28 September, 2011
To coincide with the United Nations High-Level Meeting on non-communicable diseases (NCDs), the research-based pharmaceutical industry has outlined the steps it is taking to address the rise of NCDs in the developing world.
26 September, 2011
Prosensa, the Dutch biopharmaceutical company focusing on rare diseases with an unmet medical need, announced today that they have agreed with GlaxoSmithKline (GSK) to advance three further exon skipping compounds (PRO044, PRO045 and PRO053) into the next development stage under their ongoing collaboration relationship in Duchenne Muscular Dystrophy (DMD).
20 September, 2011